Pekin Hardy Strauss Inc. Buys 800 Shares of Pfizer Inc. (NYSE:PFE)

Pekin Hardy Strauss Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 3.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,895 shares of the biopharmaceutical company’s stock after buying an additional 800 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Pfizer were worth $807,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer in the first quarter worth $315,000. Mount Yale Investment Advisors LLC raised its holdings in Pfizer by 25.7% in the first quarter. Mount Yale Investment Advisors LLC now owns 22,128 shares of the biopharmaceutical company’s stock worth $614,000 after buying an additional 4,525 shares during the last quarter. Waverly Advisors LLC lifted its stake in shares of Pfizer by 36.3% in the first quarter. Waverly Advisors LLC now owns 165,821 shares of the biopharmaceutical company’s stock worth $4,602,000 after buying an additional 44,118 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $3,992,000. Finally, Industrial Alliance Investment Management Inc. raised its holdings in Pfizer by 4.1% in the 1st quarter. Industrial Alliance Investment Management Inc. now owns 19,089 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 751 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $25.65 on Monday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market cap of $145.36 billion, a PE ratio of 34.66, a P/E/G ratio of 0.82 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day moving average price of $28.21 and a 200 day moving average price of $28.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.55%. Pfizer’s payout ratio is 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.